Drug
Ublituximab
Ublituximab: highest development phase Post-Market, developed by TG Therapeutics, United Therapeutics. 20 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- TG Therapeutics, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ublituximab NCT07389590 | Post-Market | Multiple Sclerosis |
| Ublituximab NCT07225361 | Post-Market | Multiple Sclerosis |
| Ublituximab NCT04130997 | Phase 3 | Relapsing Multiple Sclerosis (RMS) |
| Ublituximab NCT03277261 | Phase 3 | Relapsing Multiple Sclerosis (RMS) |
| Ublituximab NCT07211633 | Phase 3 | Relapsing Multiple Sclerosis |
| Ublituximab NCT05877963 | Phase 3 | Relapsing Multiple Sclerosis |
| Ublituximab NCT07220252 | Phase 2/3 | Relapsing Multiple Sclerosis |
| Ublituximab NCT03801525 | Phase 2/3 | Chronic Lymphocytic Leukemia |
| Ublituximab NCT07673744 | Phase 2 | Myasthenia Gravis |
| Ublituximab NCT04016805 | Phase 2 | Chronic Lymphocytic Leukemia |
| Ublituximab NCT02738775 | Phase 2 | Multiple Sclerosis |
| Ublituximab NCT03828448 | Phase 2 | Follicular Lymphoma |
| Ublituximab NCT07103746 | Phase 2 | Autoimmune Disorders |
| Ublituximab NCT03381170 | Phase 2 | Relapsing Remitting Multiple Sclerosis |
| Ublituximab NCT07503873 | Phase 2 | Multiple Sclerosis |
| Ublituximab NCT07680946 | Phase 2 | Schizophrenia |
| Ublituximab NCT01647971 | Phase 1/2 | Non-Hodgkins Lymphoma |
| Ublituximab NCT02013128 | Phase 1/2 | Chronic Lymphocytic Leukemia |
| Ublituximab NCT01744912 | Phase 1 | Non-Hodgkins Lymphoma |
| Ublituximab NCT06864936 | Not Applicable | Multiple Sclerosis (MS) - Relapsing-remitting |
Latest
No recent events.
Follow Ublituximab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.